LEIDEN, The Netherlands, January 26 Top Institute Pharma(TI Pharma) enables unique public-private collaborations that are extremelyvaluable for pharmaceutical research in the Netherlands. This can be read inthe Midterm Review (MTR) of the Top Institute, which was published today. Inthe report, an independent committee chaired by Cees Veerman concludes thatTI Pharma is well on its way to achieving the objectives that were determinedat the time of its establishment. The institute addresses issues with markedsocial relevance, attracts international investments and has brought forth agroup of quality researchers. The committee unanimously recommends that TIPharma should be continued in its present form.
Today, Kees van Lede, one of the members of the MTR committee, presentedthe report to Minister Ab Klink of Health, Welfare and Sport (VWS). In thereport, the committee expresses a favorable view of TI Pharma, which wasestablished in 2006 and received government funding for a period of fouryears. Every euro invested was matched by the science sector and the privatesector.
Van Lede: "As TI Pharma creates actual value, it constitutes a sensibleinvestment - one that furthermore offers a high degree of leverage. Theinstitute attracts many international investments, as the recent commitmentof EUR 53 million made by private parties illustrates. In part thanks to TIPharma, the Netherlands can compete with superstructures like Cambridge inthe UK, the Bay Area in the US and Singapore."
TI Pharma has set up an excellent research infrastructure over the pasttwo years. Universities, research institutes and larger and smallerpharmaceutical and biopharmaceutical firms work closely together to enablethe better, speedier and cheaper development of valuable medicines. Thechairman of the MTR committee, Cees Veerman, states: "The Midterm Reviewproves that with its excellent project portfolio, TI Pharma makes a valuablecontribution to the knowledge infrastructure in the Netherlands. Theindependent position that TI Pharma occupies ensures that it can play anessential role in the translation of scientific knowledge into economic andsocial value."
Both the Management Team and the Executive Board of TI Pharma feelencouraged by the conclusions of the MTR and by the recommendations thecommittee has made to further develop the top institute. Ton Rijnders, VicePresident Discovery MSD Oss and chairman of the Executive Board: "The reportis a formal confirmation of the quality and the added value of TI Pharma.Furthermore, it is a good thing that the committee has an eye for the lengthyperiod of time required to develop medicines and consequently affirms thatthe institute should be continued."
About TI Pharma
Top Institute Pharma (TI Pharma) is a public-private partnership in whichscientific and business worlds work together on groundbreaking,multidisciplinary research aimed at improving the development of sociallyvaluable medicines. Their research portfolio is based on the disease areas asspecified in Priority Medicines, a report by the World Health Organization(WHO). The knowledge gained in these projects provides an importantcontribution to better, faster and less-expensive development of valuable newmedicines.
SOURCE TI Pharma